Background {#Sec1}
==========

Malaria is a mosquito-borne infectious disease caused by parasites of the genus *Plasmodium*. The four species of *Plasmodium* that commonly infect humans are *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium ovale*, and *Plasmodium malariae*. The fifth human malaria species is *Plasmodium knowlesi*, known to cause simian malaria, which has been reported in nearly all countries from Southeast Asia and in travellers visiting these countries \[[@CR1], [@CR2]\].

In 2017, there were 219 million estimated cases of malaria worldwide, resulting in 435,000 deaths \[[@CR3]\]. In South America, the most prevalent species are *P. vivax* and *P. falciparum,* with 773,000 malaria cases estimated in 2017; 97% of these cases were found in Brazil, Colombia, Peru, and Venezuela \[[@CR1], [@CR4]\]. Recently, there has been a significant increase in the number of cases in Venezuela due to the political unrest leading to lack of available treatment \[[@CR3], [@CR5]\]. Colombia and Brazil also reported more confirmed cases compared to previous years, which shows an increase of the transmission in the region for this period \[[@CR3], [@CR6], [@CR7]\].

Chile has been certified as a malaria-free country by the World Health Organization (WHO), with no indigenously-acquired cases reported since 1945 \[[@CR8]\]. This was possible due to the implementation of an anti-malaria campaign in the early 1940s directed towards vector (*Anopheles pseudopunctipennis*) control and the prompt treatment of malaria patients \[[@CR8]\]. Between 1945 and 2001, there were 90 imported cases of malaria and five malaria-related deaths reported by the Chilean Ministry of Health \[[@CR8]\]. Malaria is a disease of immediate notification according to decree DTO N° 158/04 as part of the Emerging Diseases Surveillance of the Ministry of Health. Samples from all suspected cases are sent to the Public Health Institute of Chile (ISP) for diagnostic confirmation.

Currently, *An. pseudopunctipennis* (known malaria vector) breeding sites have been found in close proximity to residential areas in Valle de Azapa, Valle de Lluta, Quebrada de Camarones and Chaca in the Arica y Parinacota Region and in the Tarapacá Region. Additionally, González and Sallum, reported the presence of a new species of *Anopheles* with unknown vector potential in Atacama Region, northern Chile \[[@CR9]\].

For many years, the recommended malaria treatment was chloroquine (CQ) followed by sulfadoxine--pyrimethamine (SP) until resistant parasites spread worldwide. Currently, artemisinin-based combination therapy (ACT) is the first-line treatment recommended by the WHO for *P. falciparum* infected patients in countries where CQ and SP resistance has been reported \[[@CR10]\]. However, the treatment for *P. vivax* infections is chloroquine plus primaquine (CQ + PQ), with a variation of 7 or 14 days of therapy with PQ depending on the country \[[@CR4]\].

Publications reporting delayed parasite clearance following ACT in Southeast Asia \[[@CR11]--[@CR13]\] placed a worldwide alert on the importance of monitoring malaria drug resistance. In South America, the first *P. falciparum* isolates harbouring the C580Y mutation in *P. falciparum kelch 13* gene were reported in samples collected in 2010 in Guyana \[[@CR14]\]. This mutation is highly prevalent in Southeast Asia and is a confirmed marker of artemisinin resistance \[[@CR12], [@CR15], [@CR16]\]. Although ACT is still highly effective in many parts of the world, there is a serious concern about the emergence of artemisinin resistance in other parts of the world.

While malaria transmission is not known to occur in Chile, importation of malaria cases from other South American countries and other parts of the world requires proper monitoring in order to inform treatment policy. In this study, a molecular characterization of parasites from imported malaria cases was undertaken to confirm infecting *Plasmodium* species, mixed infections, and to assess the drug resistance profile of parasites. Additionally, microsatellite (MS) markers were analysed in *P. falciparum* samples to explore the presence of clusters of cases and/or polyclonal infections.

Methods {#Sec2}
=======

Malaria samples {#Sec3}
---------------

As part of national malaria surveillance, samples from suspected malaria cases throughout Chile are collected from public and private health centers and sent to the Public Health Institute of Chile (ISP) for diagnosis. A database search was performed at ISP to collect epidemiological information of patients with suspected malaria from January 2015 to December 2018 using identifiers such as: age, gender, travel history, malaria treatment, health center and region of origin. This subsequent work was part of public health surveillance and therefore Institutional Review Board (IRB)/consent was not needed, and personal information was excluded for publication.

Malaria infections in these samples at the time of diagnosis were determined by microscopy using Giemsa-stained blood smears performed at the ISP. All malaria positive patients were treated with atovaquone--proguanil and where possible, patients were followed up to ascertain clearance of their infection and were requested to report to the clinic if symptoms returned. Each health centre and treating physicians defended when and how to take additional samples for follow up, since this determination is not within the powers of the ISP.

This descriptive study used data from 268 suspected malaria cases received by the ISP during 2015--2018, period in which 65 positive patients with the *Plasmodium* spp. were confirmed through microscopy using Giemsa-stained blood smears. For molecular analysis, 46 samples were included, which was the total number of available blood samples for subsequent analysis in the laboratory. These 46 samples corresponded to 39 different patients.

DNA isolation and genotyping methods {#Sec4}
------------------------------------

Genomic DNA was extracted from 350 µl of blood using the EZ1 DNA blood Kit and the automated system EZ1 Advanced XL (QIAGEN, Valencia, CA) following the manufacturer´s instructions. Samples were eluted in 100 µl and screened using the multiplex photo-induced electron transfer (PET) real-time PCR (PET-PCR) for species confirmation \[[@CR17], [@CR18]\]. PET-PCR assays were run with 5 μl of DNA template using Agilent Mx3005pro thermocyclers (Agilent Technologies, Santa Clara, CA, USA). As previously established, a *C*~*T*~ value of \< 40 was considered positive; samples with *C*~*T*~ values above 40 were considered to be negative. DNA from confirmed *P. falciparum* samples were subsequently sequenced to examine single-nucleotide polymorphisms (SNPs) in the genes: *P. falciparum* chloroquine resistance transporter (*pfcrt*), *P. falciparum* multidrug resistance associated protein 1 (*pfmdr1*), and *P. falciparum kelch13* (*pfk13*) using protocols from previous studies \[[@CR14], [@CR19], [@CR20]\]. Sequencing of PCR products was performed using an ABI 3130 (Applied Biosystems, CA, USA). The sequence data was analysed using the Geneious Pro R8 software (Biomatters Inc, Newark, NJ).

Microsatellite analysis {#Sec5}
-----------------------

Seven *P. falciparum* neutral MS (TA1, Polyα, PfPK2, TA109, C2M34, C3M69, and 2490) located in chromosomes 2, 3, 4, 6, and 12 were amplified using previously published methods \[[@CR21], [@CR22]\] since this methodology for *P. falciparum* was already established in the laboratory. Post-PCR fluorescently labeled products were separated on an Applied Biosystems 3130 capillary sequencer and scored using GeneMarker v1.95 (SoftGenetics LLC). The presence of more than one additional allele in a single locus was interpreted as a coinfection with more than one genetically distinct clone in the patient. Missing data (no amplifications) were not considered for defining haplotypes. The size of the alleles obtained in this study was normalized with 1 bp for analysis and comparison with published alleles previously.

Results {#Sec6}
=======

*Plasmodium* species identified and origin of cases {#Sec7}
---------------------------------------------------

Microscopy analysis at the ISP confirmed that 65 of the 268 suspected cases were positive for malaria (24.3%), 16 (24.6%) were positive for *P. falciparum*, 44 (67.7%) for *P. vivax*, 2 (3.1%) for *P. ovale*, and 3 (4.6%) were mixed infections (*P. falciparum* and *P. vivax*) (Fig. [1](#Fig1){ref-type="fig"}). PET-PCR results of the 46 available samples (blood samples from all microscopy positive cases were not available), showed that 15 samples were positive for *P. falciparum*, 27 for *P. vivax,* and 4 were mixed infections (*P. falciparum*/*P. vivax*). Two samples previously identified as *P. vivax* by microscopy were reported as mixed (*P. falciparum*/*P. vivax*) infections by PET-PCR. Follow up samples (microscopy slides) were taken for 12 patients; however; only four presented symptoms and confirmed *P. vivax* infections more than 28 days after the initial infection (Table [1](#Tab1){ref-type="table"}). These patients were treated following the guidelines established by the Chilean Ministry of Health.Fig. 1Malaria positive cases confirmed by microscopy between 2015 and 2018Table 1Patients with follow up samplesPatient IDDayGenderAgeSite of infectionRegion^a^Result3D0M28BrazilMetropolitana*P. vivax*D126*P. vivax*18D0F42ColombiaAysén*P. vivax*D115*P. vivax*21D0F20PeruArica y Parinacota*P. vivax*D112*P. vivax*27D0M48ColombiaTarapacá*P. vivax*D1*P. vivax*D96*P. vivax*^a^Location of the Health Centres in Chile. The follow up samples were determined by the treating physicians

According to the epidemiological information of positive cases, 63% were male while 37% were female. The age distribution was: nearly half (47.7%; 31) of patients were 26--40 years old, 3 (4.6%) were 5--14 years old, 11 (16.9%) were 15--25 years old, 10 (15.4%) were 41--50 years old, and 9 (13.8%) were \> 50 years old; 1 patient's age was not reported. According to the travel history, 61.7% of the positive cases came from South American countries, mainly from Brazil, Colombia, Peru, and Venezuela, 24.7% of the patients reported travels to Africa, and 13.6% of the patients traveled to Central America, Asia, and other countries (Fig. [2](#Fig2){ref-type="fig"}). Additional information showed that most of the positive samples (60.5%) were collected in health centres located in the Metropolitan Region of Santiago, the capital of Chile and the main port of entry to the country. Importantly, 7.4% of the samples were collected in the Region of Arica and Parinacota and in the Region of Tarapacá, where *Anopheles* breeding sites have been described (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Origin or reported travel history of microscopy confirmed malaria cases collected between January 2015 and December 2018Fig. 3Heat map of regions reporting malaria positive cases from 2015 to 2018 using ArcGIS version 10.2 software. Samples analysed were collected from public and private health centres throughout Chile. The red arrow indicates the presence of *Anopheles* mosquito

Molecular characterization of *Plasmodium falciparum* parasites {#Sec8}
---------------------------------------------------------------

Additional genetic analysis for drug resistance markers were undertaken in the *P. falciparum* positive samples, given that drug resistance has been confirmed in this species. From a total of 19 *P. falciparum* samples, 17 were properly amplified and they were available for this analysis. All samples had the wild type *pfk13* genotype, while *pfcrt* showed mutant genotypes with the triple-mutant CV**IET** (codons 74--75--76) (Uganda, Guinea and Benin), double-mutant CVM**ET** (codons 75--76) (Colombia/Nicaragua), double-mutant **S**~tct~VMN**T** (codons 72--76) (Venezuela), and single-mutant CVMN**T** (codon 76) (Colombia) (Table [2](#Tab2){ref-type="table"}). Wild type *pfcrt* genotypes were found in samples from patients with travel history to Mozambique, Kenya, Nigeria, and the Dominican Republic, according to data provided in the clinical file. On the other hand, a quadruple *pfmdr1* mutant Y184**F**/S1034**C**/N1042**D**/D1246**Y** was found in a sample from Venezuela, a triple-mutant Y184**F**/N1042**D**/D1246**Y** in Colombia and a single mutant Y184**F** in Uganda, Nigeria and Dominican Republic. The wild *pfmdr1* genotype was found in people with travels to Guinea, Mozambique, Kenya, and Benin (Table [2](#Tab2){ref-type="table"}).Table 2Drug resistance profiles of the *P. falciparum* samplesNucleotide substitutions and changes in amino acid composition are highlighted in bold and colors: green (*pfcrt*); light blue (*pfmdr1*)

According to the MS analysis, no clustering of cases was found. Most of the samples presented polyclonal infections; however, samples from Venezuela, Dominican Republic, one sample from Nigeria and one from Mozambique showed monoclonal infections (Table [3](#Tab3){ref-type="table"}).Table 3Microsatellite profiles of the *P. falciparum* samples analysedCountry of origin/travelTA1 (Ch5)Polyα (Ch4)PfPK2 (Ch7)TA109 (Ch6)2490 (Ch10)C2M34 (Ch2)C3M69 (Ch3)Uganda (1)141--183165162--171--180151--16381234138Guinea (2)141--17112317717881228124Nigeria (1)14114717416072238124Mozambique (1)141135--165--195168--189124--133--175--19978220150Mozambique (1)14116518917581250150Mozambique (1)141--17713516217596238146Kenya (1)141--165156xx81260128Benin (1)162159168--19218778-81250146Africa (1)141150--153--186183160--19978230146Dominican Republic (1)17415015917581218124Colombia/Nicaragua (1)141--17114716216078226140Colombia (1)141--17114716016078226140Colombia (1)141--17115617117881238146Venezuela (2)14115017116378240134Venezuela (1)17118616417578240134X = no amplification

Discussion {#Sec9}
==========

The increase in the number of suspected and confirmed malaria cases in Chile might be associated with the high movement of Chileans traveling for work and/or pleasure to endemic countries, such as Brazil, Colombia, and Peru. Additionally, according to the National Institute of Statistics of Chile (INE), 746,465 immigrants (particularly from Haiti, Venezuela, Colombia, and Peru) live in Chile and it is estimated that this number has increased more than 300% compared to the previous decade (2010--2017: 471,285 and 2016--2017: 220,090) \[[@CR23]\].

Although malaria has been eliminated in Chile, globalization and cultural exchange has contributed to raising awareness of the disease and for that reason early detection of malaria cases have improved in recent years. It is necessary that health care providers in Chile obtain the travel history of patients in order to diagnose malaria promptly, notify health authorities and send samples for confirmation to the ISP. Moreover, malaria should be included in the differential diagnosis for every patient with fever who has travelled to an area where malaria is endemic \[[@CR24]\].

In this study, the most frequent malaria cases were due to *P. vivax* infections. Unfortunately, complete travel history, prophylaxis, and anti-malarial treatment could not be obtained for all cases. Nevertheless, as expected, the travel history matched the infecting species expected, with *P. vivax* infection identified in people who visited *P. vivax* endemic countries in South America and Asia and *P. falciparum* mainly from Africa. While no clusters were detected in our analysis, a cluster of *P. vivax* cases was previously reported among Chilean travellers returning from Peru \[[@CR25]\]. This highlights the need to promote the use of chemoprophylaxis in travellers, especially, in those visiting specific locations in endemic countries with high malaria transmission.

In Chile, imported malaria cases have been reported in areas that were previously considered endemic and where the presence of the *Anopheles* vector has been confirmed. The existence of imported malaria cases, which are possible reservoirs of the infection, together with the occurrence of favourable climatic conditions for competent vector species, represent a risk for the onset of autochthonous malaria cases in the country. Therefore, vigilance and continued surveillance should be warranted.

Additionally, the drug resistance profiles of the parasites are important to establish the guidelines for an appropriate treatment policy. Mutations in the *pfcrt* gene reported in this study (CVMN**T**, CV**IET**, CVM**ET**, **S**~**tct**~VMN**T**) are known chloroquine resistance markers found worldwide. Their frequency in endemic countries and the possible origin of each genotype is associated with different geographical locations \[[@CR26], [@CR27]\]. For instance, the CV**IET** genotype is typically found in Africa, in countries such as Uganda, Guinea and Benin \[[@CR26], [@CR28]--[@CR34]\]. The literature also reports the presence of this genotype in countries such as India, Thailand, Vietnam, Cambodia and Papua New Guinea \[[@CR27]\]. In South America, it has been reported in Peru, Brazil and Guyana. The **S**~**tct**~VMN**T** genotype, found in samples from Venezuela, has two possible independent origins, one in South America and one in Papua New Guinea \[[@CR20], [@CR27]\]. The CVM**ET** genotype found in a sample from a patient with travel history to Colombia and Nicaragua is mainly reported in the northern part of South America. The CVMN**T** genotype identified in two samples from Colombia is the closest to the ancestral sensitive genotype, which has been previously reported in Brazil, Colombia, Ecuador and Peru. The wild-type *pfcrt* genotype is commonly found in Central America \[[@CR27], [@CR28], [@CR35]\].

There were several *pfmdr1* alleles identified in the samples analyzed, showing single, triple, and quadruple mutants. Mutations at *pfmdr1* N86**Y** and D1246**Y**, which are common in Africa, have been linked to decreased sensitivity to chloroquine and amodiaquine, but increased sensitivity to lumefantrine, mefloquine, and artemisinins \[[@CR36]\]. Other polymorphisms, primarily seen outside Africa (including 1034**C** and 1042**D**), are associated with altered sensitivity to lumefantrine, mefloquine, and artemisinins \[[@CR36]\]. Samples from patients who traveled to Uganda, Nigeria, and the Dominican Republic showed a single mutation in codon 184 (Y184**F**), which has been previously reported in these countries \[[@CR37]--[@CR39]\]. MS analysis of *P. falciparum* confirmed that the samples analyzed were all imported, clusters or clonal expansions were not found. Furthermore, the haplotypes identified in this study, were all different (Table [3](#Tab3){ref-type="table"}). The MS alleles found in the sample from Uganda, were consistent with previous findings of these alleles in this country. The analysis of alleles showed that four of the seven loci belong to haplotypes previously described in Uganda: TA1 (183), Polyα (165), Pfpk2 (162/171/180) and TA109 (163) \[[@CR40]\].

In addition, the 2490 allele "81" found in the sample from Uganda has also been found in other African countries such as Kenya \[[@CR41]\]. Furthermore, the TA1 (141/165) and Polyα (156) alleles found in the patient returning from Kenya, are commonly found in several localities of this country \[[@CR41], [@CR42]\]. Also, the patient's sample with travel history to Guinea revealed a consistent MS pattern with a previous report from this country \[[@CR43]\]. The TA1 allele (171) found in isolates from Guinea and Colombia, has been previously reported in other countries from South and Central America but also in low frequency in Guinea and Mozambique \[[@CR35], [@CR44]--[@CR46]\]. The sample from Nigeria also revealed a consistent pattern with previous reports on loci PfPK2 and TA109 \[[@CR47]\]. The haplotypes found in samples from Colombia and Venezuela in this study, also presented alleles previously detected in both countries and in others from South America \[[@CR44], [@CR45]\]. The samples from Colombia showed a haplotype profile akin to one previously reported in Colombia, from the town of Nariño \[[@CR44]\]. One of the samples from Colombia corresponded to a patient with travel history to Nicaragua. However, the haplotype profile suggests the infection was acquired in Colombia. Finally, the MS profile identified in the sample from the Dominican Republic was similar to the one reported by Carter et al., in the Island of Hispaniola in Central America \[[@CR48]\].

An important aspect within an Integrated Surveillance System, such as the one Chile is currently implementing, is to join efforts to obtain complete epidemiological information on all cases reported, including using adequate diagnostic tools in primary health centers, following up all malaria cases, recommending appropriate prophylaxis to Chilean travellers, and ensuring the availability of appropriate drugs for malaria treatment. Currently, atovaquone--proguanil (malarone) or mefloquine could be used as the first-line treatment for patients with uncomplicated malaria in Chile \[[@CR49]\]. Among the patients included in this study, four reported post-treatment relapses with incomplete epidemiological information, such as prophylaxis, treatment and/or patient compliance with the treatment. It is worth noting that patients in Table [1](#Tab1){ref-type="table"} reported recurrent symptoms after more than 1 month. This may be attributable to a parasite relapse from latent hypnozoites, since all cases were *P. vivax* and patients did not report additional travels during or after treatment. Also, it is possible that a lack of anti-hypnozoite therapy has increased the probability of these relapses (which could be higher than 20%, according to previous reports) \[[@CR50]\].

Conclusion {#Sec10}
==========

It is essential to strengthen the malaria surveillance system in Chile, which should include complete epidemiological data, travel history, previous diagnostic results and prophylaxis or treatment given. This information is valuable to better assist patients, provide recommendations to travellers and further analyse the current malaria situation in the country. Moreover, the introduction of malaria cases in Chile has brought the presence of resistant strains from all over the world, which requires proper control and surveillance.
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